Srs Capital Advisors, Inc. Protalix Bio Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $1.07 Billion
- Q3 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 39 shares of PLX stock, worth $64. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39
Previous 39
-0.0%
Holding current value
$64
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
48Shares Held
3.5MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.58 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$718,1010.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$616,6990.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$549,7320.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$445,5000.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $82.1M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...